206 results about "Sulfonosine" patented technology

The sulfonamide or carboamide derivatives of the formula (I) and a pharmaceutical composition which comprise them as an active ingredient:(wherein A ring, B ring is carbocyclic ring, heterocyclic ring; Z1 is -COR1, -CH=CH-COR1 etc.; Z2 is H, alkyl etc.; Z3 is single bond, alkylene; Z4 is SO2, CO; Z5 is alkyl, phenyl, heterocyclic ring etc.; R2 is CONR8, O, S, NZ6, Z7-alkylene, alkylene etc.; R3 is H, alkyl, halogen, CF3 etc.; R4 is H, (substituted) alkyl etc.; n, t is 1-4).The compounds of the formula (I) can bind to receptors of PGE2 and show antagonistic activity against the action thereof or agonistic activity. Therefore, they are considered to be useful as medicine for inhibition of uterine contraction, analgesics, antidiarrheals, sleep inducers, medicine for increase of vesical capacity or medicine for uterine contraction, cathartic, suppression of gastric acid secretion, antihypertensive or diuretic agents.

The present invention provides a sulfonamide- or sulfonylurea-containing heterocyclic compounds. Specifically, it provides a heterocyclic compound represented by the formula (I), a pharmacologically acceptable salt thereof or a hydrate of them.In the formula, A is hydrogen atom, a halogen atom, a C1-C4 alkyl or alkoxy group which may be substituted with a halogen atom, or cyano group; B is an optionally substituted aryl group or monocyclic heteroaryl group, or:(wherein, the ring Q is an aromatic ring which may have nitrogen atom; and the ring M is a ring sharing a double bond with the ring Q, which ring may have a heteroatom; and the rings Q and M may share nitrogen atom); K is a single bond; T, W, X and Y are the same as or different from each other and each is =C(D)- (wherein, D is hydrogen or a halogen atom) or nitrogen atom; U and V are the same as or different from each other and each is =C(D)-, nitrogen atom, -CH2-, oxygen atom or -CO-; Z is a single bond or -CO-NH-; and R1 is hydrogen atom, etc.

The invention relates to sulfonamide-containing hydroxyethylamine protease inhibitor compounds, their process of making, composition and method of use for inhibiting retroviral proteases such as human immunodeficiency virus.

The invention features methods compositions and infusion pumps for infusing levodopa prodrugs (e.g., levodopa esters, levodopa amides, levodopa carboxamides, and levodopa sulfonamides) for the treatment of Parkinson's disease.

The present invention provides a composition and a kit for treating tumors, which permits a sulfonamide-containing heterocyclic compound to exhibit its angiogenesis inhibitory activity and antitumor activity more effectively. According to the present invention, the sulfonamide-containing heterocyclic compound can be used in treating cancers more effectively by combination with a VEGF inhibitor / FGF inhibitor.

Processes for preparing amino alcohols or salts thereof and sulfonamide substituted alcohol compounds are provided. Desirably, the sulfonamide substituted alcohol compounds are heterocyclic sulfonamide trifluoroalkyl-substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl-substituted alcohol compounds.

The invention discloses a temperature-sensitive magnetic sulfadimidine molecular imprinted adsorbent as well as a preparation method and application thereof, belonging to the technical field of preparation of environment functional materials. A gamma-Fe2O3 / SiO2 magnetic composite material is prepared by using a sol-gel method and is subjected to vinyl modification by using 3-(methylacryloyloxy) trimethoxypropylsilane; with a vinyl-modified magnetic composite material (MPS (Modified Polystyrene)-gamma-Fe2O3 / SiO2) as a substrate material, sulfadimidine as a template molecule, acrylamide as a functional monomer, N-isopropylacrylamide as a temperature-sensitive monomer, ethylene glycol-bis(methylacrylic acid) ester as a cross-linking agent and 2,2'-azobisisobutyronitrile as an initiator, a temperature-sensitive magnetic molecular imprinted polymer is prepared by using a free group polymerization process and is applied to selective recognition and separation of the sulfadimidine in an aqueous solution; and the obtained polymer has the advantages of remarkable heat and magnet stability, sensitive magnet and heat inducting effect, higher adsorption capacity, reversible adsorption / release function along with the temperature and remarkable recognition performance of a sulfadimidine molecule.

Acyl sulfonamide, peri-substituted, fused bicyclic ring compounds useful for the treatment or prophylaxis of a prostaglandin-mediated disease or condition are disclosed. The compounds are of the general formula A representative example is:

The present invention pertains to the use of certain 3,4-diarylpyazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxyl; ether; formyl; acyl; carboxy; ester; acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamide; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; R<SP>N< / SP> is independently: —H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to such compounds, pharmaceutical compositions comprising such compounds, such compounds for medical use, such compounds use in the treatment of conditions mediated by HSP90, including, for example, cancer, and use of such compounds in the preparation of medicaments for such treatments.

One aspect of the present invention relates to heterocyclic compounds comprising a sulfonamide moiety. A second aspect of the present invention relates to the use of the heterocyclic compounds comprising a sulfonamide moiety to treat diseases, afflictions or maladies caused at least in part by abnormal activity of one or more GPCRs or ligand-gated ion channels. An additional aspect of the present invention relates to the synthesis of combinatorial libraries of the heterocyclic compounds comprising a sulfonamide moiety, and the screening of those libraries for biological activity, e.g., in animal models of psychosis.

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof. 1 In the formula, R.sup.1 represents hydrogen atom, a halogen atom or cyano group; R.sup.2 and R.sup.3 are the same as or different from and each represents hydrogen atom, a C.sub.1-C.sub.4 lower alkyl group or a halogen atom; R.sup.4 represents hydrogen atom or a C.sub.1-C.sub.4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R.sup.1, R.sup.2 and R.sup.3 are hydrogen atoms, where both R.sup.2 and R.sup.3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R.sup.1 and R.sup.2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R.sup.1 is cyano group or a halogen atom, at least one of R.sup.2 and R.sup.3 should not be a hydrogen atom.

Sulfonamide-containing linkage systems for release of payload compounds from an attached targeting moiety in drug conjugates. The conjugates have the formula of [(P)-(L)]m-(T), wherein (P) is a payload compound, (L) is a linker, (T) is a targeting moiety and m is an integer from 1- to 10. Also provided are pharmaceutical compositions comprising such conjugates and there use in treating cancer.

Substituted sulfonamide derivatives, a process for their preparation, pharmaceutical compositions containing these compounds, and to the use of substituted sulfonamide derivatives in the treatment or inhibition of pain and / or various disorders or disease states.

This invention discloses a way for fast checking the immunological colloid gold test strip left by the sulfadiazine and it's making method, which belongs to the immunochemistry fast measure technique filed. The test strip of this invention includes: the sample mat, the combining mat, the cellulose nitrate film, the sopping mat and the PVC backing, which characterized in that the sample mat, the combining mat, the cellulose nitrate film and the sopping mat inhibit the PVC backing in order; the combining mat is marked with the anti-sulfadiazine monoclonal antibody-colloid gold marker, and the monoclonal antibody is obtained by the secretion of the hybridomas cell line BDRXN(the conserving number is CCTCC-C200522) The cellulose nitrate film is covered with the checking line that is composed of the sulfadiazine-carrier protein joined matter and the quality control line that is composed of the rabbit-anti-mouse IgG. The test strip of this invention has the following advantages: the sensitivity is high, the special isomerism is strong, the operation is simple and checking is fast and exactly.

The present invention aims to provide a novel low-molecular-weight compound having an orexin agonist activity, which is expected to be useful as a superior agent for the treatment or prophylaxis of narcolepsy. The present invention provides a compound showing superior orexin agonist activity which is represented by the formula (I)wherein each symbol is as defined in the DESCRIPTION, and a pharmaceutically acceptable acid addition salt thereof, as well as an orexin agonist containing the compound or a pharmaceutically acceptable acid addition salt thereof.

The present invention creates a novel antiangiogenic agent and provides an antitumor agent which shows high safety as compared with conventional antitumor agents, has a sure effect and is able to be administered for a long period. That is, it provides an indole compound represented by the following formula (I), its pharmacologically acceptable salt or hydrates thereof.In the formula, R1 represents hydrogen atom, a halogen atom or cyano group; R2 and R3 are the same as or different from and each represents hydrogen atom, a C1~C4 lower alkyl group or a halogen atom; R4 represents hydrogen atom or a C1~C4 lower alkyl group; and the ring A represents cyanophenyl group, aminosulfonylphenyl group, aminopyridyl group, aminopyrimidyl group, a halopyridyl group or cyanothiophenyl group, provided that the case where all of R1, R2 and R3 are hydrogen atoms, where both R2 and R3 are hydrogen atoms or where the ring A is aminosulfonyl group and both R1 and R2 are halogen atoms is excluded. Further, when the ring A is cyanophenyl group, 2-amino-5-pyridyl group or a 2-halo-5-pyridyl group and R1 is cyano group or a halogen atom, at least one of R2 and R3 should not be a hydrogen atom.

Processes for preparing amino alcohols or salts thereof and sulfonamide substituted alcohol compounds are provided. Desirably, the sulfonamide substituted alcohol compounds are heterocyclic sulfonamide trifluoroalkyl-substituted alcohol compounds or phenyl sulfonamide trifluoroalkyl-substituted alcohol compounds.

The present invention is directed to a new class of 6-sulfonamide quinoline and chromene derivative and to their use as androgen antagonists.

Certain substituted sulfonamide derivatives selectively modulate the cardiac sarcomere, for example by potentiating cardiac myosin, and are useful in the treatment of systolic heart failure including congestive heart failure.

The sensitivity of a tumor cell to a sulfonamide compound or the anti-tumor effect of a sulfonamide compound can be examined by determining the expression level of EGFR1 in the tumor cell and employing the variation in the EGFR1 expression level as a measure. Thus, a method for determination of the sensitivity of a tumor cell to a sulfonamide compound; a method for determination of the anti-tumor effect of a sulfonamide compound; and a test kit for use in these methods are provided.

Provided are compounds, pharmaceutical compositions and methods of treatment or prophylaxis of an inflammatory condition, in particular asthma. The compounds are of the general Formula I, or a pharmaceutically acceptable salt, ester, prodrug or derivative thereof:wherein:X and Y are independently selected from —CH2— or —CH2—CH2—; Z is selected from S(O)m or Se(O)m and m is 0, 1 or 2; R1 is optionally substituted heteroaryl or heterocyclic; R2 is selected from the group consisting of hydrogen, C1-C6 straight alkyl, and C1-C6 branched alkyl, wherein all may be optionally substituted; and R3 and R4 are alkyl.

The invention discloses novel N-4-phenylsulfonamido--N'-1-desoxy-(2-desoxy-2-substituted-amino)-beta-D-glucopyransoylthiocarbamide compounds with the general formula disclosed in the specification, which have the activity of inhibiting carbonic anhydrase and further achieve the effect of resisting tumor metastasis and invasion. The compounds structurally have the three active segments sulfamine, substituted glucosamine and thiocarbamide, and the three active segments and Zn<2+> ions in the carbonic anhydrase form coordinate bonds, thereby inhibiting the catalytic activity of the enzyme and performing the function of resisting tumor metastasis and invasion. Thus, the compounds have application potential in the aspect of antitumor drugs. In the general formula, R is defined in the specification.

[PROBLEMS] To provide: a black compound which is for use in ink-jet recording or writing utensils, is excellent in ozone resistance, light resistance, moisture resistance, and color rendering, and gives a recording fluid having satisfactory storage stability; and an ink composition containing the compound. [MEANS FOR SOLVING PROBLEMS] The black compound is a trisazo compound represented by the following formula (1) or a salt thereof. (1) [In the formula (1), R1 and R2 each independently represents hydrogen, carboxy, sulfo, hydroxy, a C1-4 alkyl, C1-4 alkoxy, or sulfo group optionally substituted by C1-4 alkoxy, an optionally carboxylated C1-4 alkoxy group, etc.; and A represents phenyl or naphthyl (provided that the phenyl and naphthyl groups may be substituted by halogeno, carboxy, sulfo, sulfamonyl optionally substituted by alkyl or phenyl, nitro, etc.).]

The invention discloses a triphosgene method for synthesizing benzene sulphanilamide, the intermediate of glimepiride, a drug for Type ii Diabetes Mellitus. Triphosgene is slowly dropped into a solution which contains phenethylamine and 3-ethyl-4-methyl pyrroline ketone, at a controlled temperature, so that N-[2-(3-ethyl-4-methyl-2-oxidation-3-pyrroline-1-formylamino)ethyl]-benzene (3) is obtained; the product reacts with chlorosulfonic acid to generate sulfonated product; the sulfonated product reacts with ammonia water to generate crude product benzenesulfonamide; the crude product is refined through solvent treatment to generate fine product; the reaction formula is show in the specification. The triphosgene method is simple in technology, simple in operation and high in yield; compared with the conventional method of phosgene, the solid phosgene (triphosgene) method is safer and is convenient to operate.

The present invention is directed to a compound of Formula (I): and pharmaceutically acceptable salts, solvates, hydrates or stereoisomers thereof, which are useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.

The invention discloses a method and special immune affinity adsorbent for extracting quinolone compound and / or sulfonamide compound. The immune affinity adsorbent consists of a solid-phase carrier and Norfloxacin monoclonal antibody and / or sulfamethoxazole monoclonal antibody coupled with the carrier, wherein the Norfloxacin monoclonal antibody and the sulfamethoxazole monoclonal antibody are obtained by taking Norfloxacin hapten, sulfamethoxazole hapten and carrier protein conjugate as immunogen; the quinolone compound is at least one of the following 13 types of compounds: Ciprofloxacin, Norfloxacin, Pefloxacin, Ofloxacin, Enoxacin, Marbofloxacin, Lomefloxacin, Danofloxacin, Enrofloxacin, Sarafloxacin, Difloxacin, Oxolinic acid and Flumequine; and the sulfonamide compound is at least one of the following 6 types of compounds: sulfapyridine, sulfathiazole, sulphapyridine, sulfamethizole, sulfamonomethoxine and sulfamethoxazole.

The invention discloses a method for detecting sulfonamide and beta-lactam antibiotics in livestock and poultry breeding wastewater. The method comprises the following steps: sequentially centrifugingand filtering a to-be-detected water sample; adding deionized water into the obtained filtrate for dilution; adding Na2EDTA, adjusting the pH, carrying out solid-phase extraction treatment on the obtained pre-treated water sample, carrying out negative-pressure leaching treatment and normal-pressure elution treatment on a solid-phase extraction column subjected to the solid-phase extraction treatment, collecting eluent, and then carrying out nitrogen blowing and constant volume treatment to obtain an antibiotic solution to be detected; and carrying out antibiotic content detection on the antibiotic solution to be detected by adopting a high performance liquid chromatography-tandem mass spectrometry method. According to the detection method disclosed by the invention, a solid phase extraction-liquid chromatography tandem mass spectrometry method is adopted, and various process conditions and parameters are selected and determined, so that the detection method can be used for rapidly and accurately detecting antibiotics in water and detecting sulfonamide and beta-lactam antibiotics in the livestock and poultry breeding wastewater at the same time.

The invention provides a sulfonamide antibiotic synergistically degraded bacteria and an application thereof. The sulfonamide antibiotic synergistically degraded bacteria comprise arthrobacterium P27and nocardioides N27, wherein the arthrobacterium P27 is preserved in China General Microbiological Culture Collection Center on December 03, 2019, and the preservation number is CGMCC No. 19070; andthe nocardioides N27 is preserved in the China General Microbiological Culture Collection Center on December 03, 2019, and the preservation is CGMCC NO. 19071. According to the technical scheme, compounding of the two strains of bacteria can synergistically complete degradation of sulfamethoxazole and an azacyclo product 3-amino-5-methylisoxazole; and in addition, the strain P27 can degrade one side of benzene rings of various sulfonamide antibiotics, the degradation substrate spectrum is wide, and a new idea and a new strain resource are provided for deep removal of the sulfonamide antibiotics.

The invention provides a method for separating and measuring sulfonamide-class impurities in celecoxib through HPLC (High Performance Liquid Chromatography) and application. According to the chromatographic column of the high performance liquid chromatography, phenyl bonded silica gel is adopted as a stationary phase, and an inorganic acid-organic phase is adopted as a mobile phase to perform gradient elution; the temperature of the stationary phase ranges from 25 to 35 degrees Celsius, the flow rate of the stationary phase ranges from 0.9 to 1.1 mL / min, and the detection wavelength of the stationary phase ranges from 248 to 250 nm; the temperature of a sample chamber ranges from 4 to 10 degrees Celsius; and the initial volume ratio of the inorganic acid to the organic phase of the mobilephase ranges from (72:28) to (85:15). The method of the invention can simultaneously separate and quantitatively measure three kinds of sulfonamide-class impurities, namely, sulfonamide, 4-SAPH and YF042-14 in celecoxib and chemical medicines containing sulfonamide-class impurities without being interfered, has a good peak pattern, and can completely and effectively control the quality of the celecoxib raw material. The method has the advantages of high specificity, high sensitivity and good accuracy.